Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis
American Journal of Translational Research · 2026 · 18 (5) · 3864-3885
DOI: 10.62347/pmfb6027 ↗At a glance
Übersichtsarbeit in American Journal of Translational Research, 2026. Written by Shengbo Xu and 3 co-authors. Institution: Guangxi University of Chinese Medicine Nanning 530200, Guangxi, P. R. China. The full text is freely available in PubMed Central.
Abstract (original language)
Není k dispozici žádný abstrakt.
Subjects
Author keywords
Authors and institutions
- Guangxi University of Chinese Medicine Nanning 530200, Guangxi, P. R. China.
- Department of Respiratory and Critical Care Medicine, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine Nanning 530011, Guangxi, P. R. China.
Cite
APA
Xu, S., Li, L., Lu, W., & Liu, R. (2026). Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. American Journal of Translational Research, 18(5), 3864-3885. https://doi.org/10.62347/pmfb6027
Vancouver
Xu S, Li L, Lu W, Liu R. Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. American Journal of Translational Research. 2026;18(5):3864-3885. doi:10.62347/pmfb6027
BibTeX
@article{Xu2026,
author = {Xu, Shengbo and Li, Lan and Lu, Wen and Liu, Rui},
title = {Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis},
journal = {American Journal of Translational Research},
year = {2026},
volume = {18},
number = {5},
pages = {3864--3885},
doi = {10.62347/pmfb6027}
}
EUVIMED